Native and pegylated forms of L-asparaginase: the assessment of effectiveness and toxicity in acute lymphoblastic leukemia treated with Berlin–Frankfurt–Munster (BFM) protocol
Open Access
- 8 December 2024
- journal article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 44-51
Abstract
Background. L-asparaginase is an integral part of chemotherapy regimens in treatment of patients with acute lymphoblastic leukemia (ALL). However, the use of L-asparaginase is limited due to wide range of adverse reactions. Our research demonstrates the toxicity effects and treatment results in patients with ALL who received native and pegylated (EG) L-asparaginase.Materials and methods. From 2013 to 2023 in the study 199 patients with newly diagnosed ALL were enrolled. Patients were treated according to the ALL IC-BFM 2009 protocol including L-asparaginase. The average age of patients was 4.6 (1–18) years. B-ALL was diagnosed in 175 (87.9 %) patients, T-ALL in 24 (12.1 %) patients. Native L-asparaginase was used in the therapy of 51 (25.6 %) patients; if allergic reactions occured, 72 (36.2 %) patients received EG asparaginase. In 76 (38.2 %) patients treatment protocol included only EG-asparaginase without native L-asparaginase history.Results. The most common adverse event was a hypersensitivity reaction – 27.6 % (n = 55), which was more common in the cohort of patients receiving native L-asparaginase. The incidence of hypercoagulation for patients treated with native L-asparaginase was 4 % and 0 % – for EG-asparaginase group. Hypocoagulation, presented as hypofibrinogenemia registered in 13 % of patients received native L-asparaginase and in 35 % for EG-asparaginase group. ancreatitis, complicated ALL treatment were diagnosed in 4 % after native L-asparaginase and 1 % after EG-asparaginase. The best 5‑year survival rates were observed in the group of patients who initially received EG-asparaginase – overall and eventfree survival were 100 and 87.5 (11.7) %, respectively (р 0.05).Conclusion. Despite the absence of convincing survival benefit in patients with newly diagnosed ALL treated with EG-asparaginase, the toxicity profile was better in contrast to native L-asparaginase.Keywords
This publication has 24 references indexed in Scilit:
- Management of infusion-related reactions in cancer therapy: strategies and challengesESMO Open, 2024
- Long‐term effects of asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2023
- PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysisCochrane Database of Systematic Reviews, 2023
- Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemiaLeukemia Research Reports, 2022
- Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemiaLeukemia & Lymphoma, 2022
- SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2021
- Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional StudyClinical Lymphoma Myeloma and Leukemia, 2020
- Successful Management of l-Asparaginase–Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase–Associated Pancreatitis?Clinical Therapeutics, 2020
- Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group reportCancer, 2015
- Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseJournal of Adolescent and Young Adult Oncology, 2015